RCELNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as AVHHL
AVITA Medical, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$13.14+0.10 (+0.77%)
Close on Oct 19, 2026
- Market cap
- $404.05M
- P/E (TTM)
- –
- Dividend yield
- –
AVITA Medical, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPK | $36.80M | $35.50M | $35.80M | $36.40M | $35.70M | $27.01M | $17.50M | – | – | – | – | – | 48.7% | +3.1% |
| PermeaDerm | – | – | $6.00M | – | – | – | – | – | – | – | – | – | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $72.55M | $69.60M | $68.79M | $69.68M | $72.70M | $69.38M | $62.16M | $57.14M | $51.06M | $47.47M | $46.36M | $28.96M | 95.9% | -0.2% |
| Japan | $1.85M | $1.89M | $2.09M | $1.86M | $1.64M | $1.61M | $1.43M | $2.30M | $2.49M | $2.81M | $3.37M | – | 2.5% | +12.8% |
| United Kingdom | $691.00K | $653.00K | $486.00K | $472.00K | $183.00K | $188.00K | $196.00K | $196.00K | $182.00K | $142.00K | $141.00K | – | 0.9% | +277.6% |
| Australia | $354.00K | $200.00K | $200.00K | $340.00K | $314.00K | $335.00K | $312.00K | $198.00K | $205.00K | $177.00K | $222.00K | – | 0.5% | +12.7% |
| European Union | $182.00K | $0 | $49.00K | $49.00K | $49.00K | $152.00K | $155.00K | – | – | – | – | – | 0.2% | +271.4% |
From the segment and revenue-disaggregation notes of AVITA Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.